β-Boswellic acid

β-Boswellic acid at a Glance

beta-Boswellic acid is a pentacyclic triterpene acid and one of the most abundant boswellic acids in frankincense resin.

Abundance is not activity, and this compound is the clearest example on the site. Frankincense’s anti-inflammatory reputation rests on 5-lipoxygenase inhibition — but that comes from the 11-keto relatives AKBA and KBA, not from beta-boswellic acid, which lacks the keto group and is a far weaker inhibitor.

So the most plentiful boswellic acid is not the one doing the work, which matters when reading extracts standardised to “total boswellic acids.”

What It's Used For

β-Boswellic acid (BBA) is a pentacyclic triterpene acid and one of the most abundant boswellic acids in frankincense (Boswellia serrata) resin ^{9Reference 9Mannino G et al. · 2016Quantitative determination of 3-O-acetyl-11-keto-β-boswellic acid (AKBA) and other boswellic acids in Boswellia sacra Flueck and Boswellia serrata RoxbView study →}.

The single most important framing point is a family distinction: frankincense’s anti-inflammatory reputation rests on the 11-keto boswellic acids — AKBA and KBA — which are the potent 5-lipoxygenase inhibitors and the standardization markers of Boswellia extracts. BBA lacks the C-11 keto group, so it is a weak and different actor on 5-LOX ^{1Reference 1Sailer ER et al. · 1996Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activityView study →}.

Its own preclinical mechanisms run through cathepsin G, topoisomerase and NF-κB instead ^{2,3,4Reference 2Tausch L et al. · 2009Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincenseView study →Reference 3Syrovets T et al. · 2000Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIαView study →Reference 4Syrovets T et al. · 2005Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-α induction in monocytes by direct interaction with IκB kinasesView study →}.

Two further facts shape the page: all human “Boswellia” efficacy is for the whole extract standardized to boswellic acids, not isolated BBA ^{11,12Reference 11Majeed M et al. · 2019RCTA pilot, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the kneeView study →Reference 12Kirste S et al. · 2011RCTBoswellia serrata acts on cerebral edema in patients irradiated for brain tumours: a prospective, randomised, placebo-controlled, double-blind pilot trialView study →}, and boswellic acids have poor oral bioavailability that improves substantially with a fatty meal ^{6,7Reference 6Sterk V et al. · 2004Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteersView study →Reference 7Skarke C et al. · 2012Increased bioavailability of 11-keto-β-boswellic acid following single-dose frankincense-extract administration after a standardised meal in healthy male volunteersView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. BBA-specific isolate evidence is preclinical and thinner than the AKBA story, so scores stay low by design. Each application links to its write-up.

01Anti-inflammatory (OA, IBD)Shaky40%Human RCTs of the standardized extract, not the isolate ^{11,12Reference 11Majeed M et al. · 2019RCTA pilot, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the kneeView study →Reference 12Kirste S et al. · 2011RCTBoswellia serrata acts on cerebral edema in patients irradiated for brain tumours: a prospective, randomised, placebo-controlled, double-blind pilot trialView study →}

02AnticancerShaky26%Cell-line + mechanism, often the acetylated congeners ^{5,3Reference 5Liu JJ et al. · 2002Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent of Fas/Fas-ligand interaction in colon cancer HT-29 cellsView study →Reference 3Syrovets T et al. · 2000Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIαView study →}

03Cathepsin-G inhibitionShaky24%Enzyme + cell mechanism (BBA-plausible) ^{2Reference 2Tausch L et al. · 2009Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincenseView study →}

04Topoisomerase / NF-kBShaky20%Biochemical, for acetyl-boswellic acids ^{3,4Reference 3Syrovets T et al. · 2000Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIαView study →Reference 4Syrovets T et al. · 2005Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-α induction in monocytes by direct interaction with IκB kinasesView study →}

Mechanisms

Pharmacokinetics

Load-bearing and the honest limiter. Boswellic acids have poor oral bioavailability — high lipophilicity, low aqueous solubility, and extensive first-pass handling and efflux limit systemic and CNS exposure, and an in-vitro panel of the six major boswellic acids found sharply differing permeability and metabolic stability with limited predicted brain availability ^{8Reference 8Gerbeth K et al. · 2013In-vitro metabolism, permeation and brain availability of six major boswellic acids from Boswellia serrata gum resinsView study →}. Crucially, a high-fat meal markedly increases absorption: a standardized fatty meal raised plasma boswellic-acid levels in healthy volunteers ^{6Reference 6Sterk V et al. · 2004Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteersView study →}, and specifically increased 11-keto-β-boswellic acid exposure several-fold after a single frankincense-extract dose ^{7Reference 7Skarke C et al. · 2012Increased bioavailability of 11-keto-β-boswellic acid following single-dose frankincense-extract administration after a standardised meal in healthy male volunteersView study →}. KBA and AKBA are the routinely measured plasma markers; BBA, though abundant in the resin, is used less often as the quantitative marker. The practical implication: dose with a fatty meal, because unfed absorption is poor.

Clinical trials

There is no human trial of isolated β-boswellic acid. The human evidence base is the whole B. serrata extract standardized to boswellic acids — a knee-osteoarthritis RCT ^{11Reference 11Majeed M et al. · 2019RCTA pilot, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the kneeView study →} and a cerebral-edema RCT ^{12Reference 12Kirste S et al. · 2011RCTBoswellia serrata acts on cerebral edema in patients irradiated for brain tumours: a prospective, randomised, placebo-controlled, double-blind pilot trialView study →} — in which BBA is present as an abundant constituent but is not the standardization target and cannot be credited as the isolated active.

Last checked: July 2026.

Toxicity & Safety

Frankincense extract is well tolerated in trials, but the tolerability record belongs to the extract, not to this molecule — and the boswellic acid family is not uniformly benign.

Safety at a Glance

✅ Low / no toxicityDrug interactions

• Extract is generally well tolerated in trials. The commonest effects are mild GI upset — nausea, reflux, diarrhea.
• Avoid in pregnancy and breastfeeding. Traditional emmenagogue reputation and no reproductive data.
• Possible CYP interactions. Boswellic acids modulate cytochrome-P450 activity in vitro; plausible but unproven in people.
• Additive caution with anti-inflammatory or anticoagulant regimens. The fraction has leukotriene and NF-κB activity.
• Do not import AKBA’s toxicity signal. The zebrafish developmental/cardiotoxicity report applies to AKBA, not to BBA.

Full Safety & Interactions Detail

Boswellia serrata extract is generally well tolerated in trials, with the most-reported effects being mild gastrointestinal upset (nausea, reflux, diarrhea) ^{11,12Reference 11Majeed M et al. · 2019RCTA pilot, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the kneeView study →Reference 12Kirste S et al. · 2011RCTBoswellia serrata acts on cerebral edema in patients irradiated for brain tumours: a prospective, randomised, placebo-controlled, double-blind pilot trialView study →}; there is no isolated-BBA human safety data. Boswellic acids modulate cytochrome-P450 activity in vitro, a plausible but unproven basis for interactions with Cyp-metabolized drugs, and additive caution with anti-inflammatory or anticoagulant regimens is prudent given the fraction’s leukotriene/NF-κB activity. One family caveat: the potency and safety signals differ across the boswellic acids — a developmental/cardiotoxicity signal reported in zebrafish applies to AKBA, not BBA, and should not be transferred here, though it is a reminder the family is not uniformly benign.

Dosage

There is no validated human dose for isolated β-boswellic acid, and nothing here is a recommendation. Human data use standardized B. serrata extract — commonly ~100–250 mg/day of a high-AKBA extract, or ~300–400 mg two to three times daily of a ~30–65% boswellic-acid extract in older osteoarthritis trials ^{11,12Reference 11Majeed M et al. · 2019RCTA pilot, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the kneeView study →Reference 12Kirste S et al. · 2011RCTBoswellia serrata acts on cerebral edema in patients irradiated for brain tumours: a prospective, randomised, placebo-controlled, double-blind pilot trialView study →} — and absorption improves substantially when taken with a fatty meal ^{6,7Reference 6Sterk V et al. · 2004Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteersView study →Reference 7Skarke C et al. · 2012Increased bioavailability of 11-keto-β-boswellic acid following single-dose frankincense-extract administration after a standardised meal in healthy male volunteersView study →}. Those figures describe the extract in which BBA occurs, not the isolated molecule.

References

1. Sailer ER, et al. (1996). Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. British Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/8646405/
2. Tausch L, et al. (2009). Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense. The Journal of Immunology. https://pubmed.ncbi.nlm.nih.gov/19648270/
3. Syrovets T, et al. (2000). Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIα. Molecular Pharmacology. https://pubmed.ncbi.nlm.nih.gov/10860928/
4. Syrovets T, et al. (2005). Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-α induction in monocytes by direct interaction with IκB kinases. The Journal of Immunology. https://pubmed.ncbi.nlm.nih.gov/15611276/
5. Liu JJ, et al. (2002). Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent of Fas/Fas-ligand interaction in colon cancer HT-29 cells. Carcinogenesis. https://pubmed.ncbi.nlm.nih.gov/12507932/
6. Sterk V, et al. (2004). Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/15643550/
7. Skarke C, et al. (2012). Increased bioavailability of 11-keto-β-boswellic acid following single-dose frankincense-extract administration after a standardised meal in healthy male volunteers. Journal of Clinical Pharmacology. https://pubmed.ncbi.nlm.nih.gov/22167571/
8. Gerbeth K, et al. (2013). In-vitro metabolism, permeation and brain availability of six major boswellic acids from Boswellia serrata gum resins. Fitoterapia. https://pubmed.ncbi.nlm.nih.gov/23103296/
9. Mannino G, et al. (2016). Quantitative determination of 3-O-acetyl-11-keto-β-boswellic acid (AKBA) and other boswellic acids in Boswellia sacra Flueck and Boswellia serrata Roxb. Molecules. https://pubmed.ncbi.nlm.nih.gov/27782055/
10. Efferth T, Oesch F (2022). Anti-inflammatory and anti-cancer activities of frankincense: targets, treatments and toxicities. Seminars in Cancer Biology. https://pubmed.ncbi.nlm.nih.gov/32027979/
11. Majeed M, et al. (2019). A pilot, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/30838706/
12. Kirste S, et al. (2011). Boswellia serrata acts on cerebral edema in patients irradiated for brain tumours: a prospective, randomised, placebo-controlled, double-blind pilot trial. Cancer. https://pubmed.ncbi.nlm.nih.gov/21287538/

View all 12 references▾